Nucala sales

Up 30% in Q1 vs Q1 2020. Leadership in that division is questionable at best but Nucala continues to have strong growth.

 

If Sanofi/Regeneron sold/marketed Nucala sales would be through the roof, Nucala is a better drug but GSK is too focused on things that don’t matter ( metrics, profitability). All the Dupixent people are focused on is getting more patients on Dupixent.

 

Worst marketing directors in the company........probably in the industry........hired and trained by the Lilly moron MJ who they finally threw out with the rest of the Lilly crowd....

 

We are and will be fine. A lot of life left with Nucala.

 

Nucala will be number 3 or 4 prescribed in the class by the end of 2021. This drug has one year left max!!

 

Nice try. So many trolls. Nucala will be just fine.

 

Nucala is a good product but incompetent leadership always brings down good products eventually

 

It will still hit 1.3 billion this year , nowhere near finished . 1 year left is truly the comment of an idiot

 

Sounds like a Richard response. Filled with puffery, insults and grammatical errors.

 

Sooooooo, they are just going to shut down and quit producing a 1.3 billion dollar product ? Why wound they do that ? Or do you mean something else by “one year left max!!!” ?

 

Currently only 2 other drugs in same class as Nucala ( Fasenra and Cinqair). You really think these 2 plus another drug that doesn’t even exist yet are going to outsell Nucala ? Fasenra may eventually but not in the next couple of years. At least educate yourself on Nucala before making silly comments.

 

Excuse me dick head, so of course you dont want to include Dupixent which may not be in the same class but certainly is taking tons of Nucala business and will continue to do so in the SEVERE ASHTMA market. So you do the math little dick brain, by the end of the year Nucala will be 3rd in sales behind Dupi and Fasenra even when you only look at the SA market, bank on it!!!

 

Dupixent yes Fasenra will pass Nucala in 2023

 

With AZ better contracting I think Fasenra overtakes Nucala by year end but Nucala still has several years of shelf life for the sales force.

 

You seem angry

 

Does anybody know why that Marketing VP left the company so abruptly? Things must be too good I guess......

 

The Nucala one

 

Ummm... it’s spelled as follows: A-S-T-H-M-A. Asthma... Repeat after me, ASTHMA. Good. Continue on please, hit your KPI’s and see all your targets. Corona is over folks (at least according to GSK leadership)! LOL

 

You need to get laid.

 

Dupixent is not the only thing to be worried about. Amgen’s new agent looks strong. Very crowded space to be playing in.